7, Oct 2026
Hoola Health Acquires UpTodd and Unveils Hoola 1000 for a Child’s First 1,000 Days
Bengaluru, Oct 07th, 2026: Hoola Health, a paediatric healthcare company building an integrated care ecosystem for children and families, today announced the acquisition of UpTodd, an early-childhood development platform, and unveiled Hoola 1000, a paediatrician-led programme that guides families from pregnancy through a child’s second birthday. Registrations for the programme are now open, ahead of its December 2026 launch in Bengaluru. Built on UpTodd’s early-childhood content and parent-engagement capabilities, Hoola 1000 combines guided paediatric care, specialist support and everyday guidance in one place.
The programme takes its name from the first 1,000 days of a child’s life, from conception to the second birthday, widely recognised as the most important window for a child’s growth, brain development and long-term health.
For most families, pregnancy comes with a clear structure of regular check-ups, scans and antenatal classes. After birth, that structure largely falls away. Paediatric visits in the first two years tend to be brief and built around a vaccine or an illness, and parents often leave without knowing what to expect next, what to watch out for or what is perfectly normal. Once they leave the clinic, the everyday questions are theirs to answer alone, with advice pieced together from search engines and social media. And many urban parents are raising children away from the extended families who once guided them through these early years.
Breastfeeding is a clear example of what happens when support thins out after birth. Nearly four in ten babies in Karnataka are not exclusively breastfed through their first six months, a figure that has barely moved in recent years, according to the National Family Health Survey (NFHS-6). For many families, what is missing is not intent, but the right guidance at the right moment.
Hoola 1000 is designed to give parents that village, a clinical one, starting with the paediatric visit itself. At each Guided Check-in, a Hoola paediatrician walks parents through how their child is growing, what to expect in the weeks ahead, what to watch out for and what they do not need to worry about. Beyond the check-ins, families have unlimited consultations with Hoola paediatricians and specialists, including lactation consultants, nutritionists, sleep coaches and developmental therapists, over chat, video or in person at a Hoola clinic, with no per-consultation charges. A dedicated Care Concierge acts as each family’s single point of contact, helping parents with their questions, connecting them with the right specialist and managing appointments all seven days a week, and keeping track of every vaccination, with paediatricians guiding parents on each vaccine.
Alongside clinical care, the programme gives parents structured, everyday support at home:
• Daily nutrition plans and an on-demand recipe library, matched to the child’s age and feeding stage
• Weekly play and development activities suited to the child’s developmental stage
• Monthly milestone reports that help parents track growth and development
• Stage-wise toy and activity kits delivered home as the child grows
Commenting on the unveiling, Deeksha Senguttuvan, Founder & CEO, Hoola Health, said, “When a baby is born, parents have a hundred questions, and a typical paediatric visit answers very few of them. Families come in for a vaccine or when their child is unwell, and leave without a sense of what’s coming next. We built Hoola 1000 so that every visit helps parents understand what to expect, what to watch for and what not to worry about, and so that the support doesn’t stop when they leave the clinic. Across more than 20,000 families at Hoola, and through UpTodd’s work with over 100,000 parents, we have seen how much that guidance matters. We want Hoola to be the partner parents turn to through every stage of early childhood, not just when their child is sick.”
The unveiling follows Hoola Health’s acquisition of UpTodd, an early-childhood development platform offering personalised, milestone-driven programmes across child development, nutrition and parenting guidance. UpTodd has engaged more than 100,000 families and built a base of over 10,000 paying customers. The acquisition brings UpTodd’s content, milestone-tracking and parent-engagement capabilities into Hoola Health, where they are combined with Hoola’s clinical expertise to shape Hoola 1000. UpTodd’s founders, Abhishek Singh, Devesh Kaushik and Richa Singh, have joined Hoola Health to lead new initiatives, technology and the therapy business respectively. Financial terms of the transaction were not disclosed.
Hoola 1000 will launch in Bengaluru in December 2026, with pricing and programme details to be announced at launch.
- 0
- By Neel Achary
7, Oct 2026
RBI Turns Cautious, Raises Repo Rate to 5.50 pc Amid Inflation and Global Uncertainty
New Delhi, Oct 7: The Reserve Bank of India (RBI) has increased the benchmark repo rate by 25 basis points to 5.50 per cent, taking a cautious approach as rising inflation, higher crude oil prices and growing global economic risks put pressure on the domestic economy.
The decision was announced on Wednesday after a three-day meeting of the six-member Monetary Policy Committee (MPC), chaired by RBI Governor Sanjay Malhotra.
Along with the repo rate hike, the RBI raised the Standing Deposit Facility (SDF) rate to 5.25 per cent, while the Marginal Standing Facility (MSF) rate and bank rate were adjusted to 5.75 per cent.
The rate increase comes after the central bank had maintained the repo rate at 5.25 per cent for an extended period. It also marks the first increase in the repo rate since February 2023, reflecting a shift in the policy environment as inflationary pressures have become more pronounced.
Inflation has been one of the key factors behind the RBI’s decision. India’s Consumer Price Index (CPI) inflation rose to 4.82 per cent in August from 4.45 per cent in July, bringing price pressures closer to the upper end of the RBI’s tolerance band.
The global environment has also become more challenging. Crude oil prices have moved above $100 a barrel, partly due to escalating tensions in West Asia. A sustained rise in oil prices could increase input, transportation and energy costs across several sectors and add to inflationary pressures.
Global bond yields and inflation trends have further complicated the policy outlook. With several major economies facing renewed price pressures, the room for central banks to maintain easier monetary conditions has narrowed.
Domestic food inflation remains another area of concern. Strong El Nino conditions and below-normal rainfall in October could affect Rabi crop production, potentially creating additional pressure on food prices in the coming months.
SBI Research had earlier indicated that the balance of risks favoured a 25-basis-point rate increase, citing broader inflationary pressures, changing global macroeconomic conditions, liquidity developments and renewed repricing of risks in financial markets.
The RBI’s latest decision underlines its priority of containing inflation while keeping a close watch on growth and financial stability. Borrowers, banks, businesses and investors will now track upcoming policy meetings for further signals on interest rates and liquidity conditions.
The repo rate hike could have implications for borrowing costs across the economy, particularly for loans linked to external benchmarks, while also influencing deposit rates and financial market sentiment.
7, Oct 2026
Biodeal Pharmaceuticals Expands into Sterile Injectables with Acquisition of Biological E Facility
Mumbai, 07 October 2026: Biodeal Pharmaceuticals, a leading Contract Development and Manufacturing Organisation (CDMO), has acquired a sterile injectable manufacturing facility in Paonta Sahib, Himachal Pradesh – one of the largest manufacturing facilities in the state – from Biological E Limited. The acquisition marks a strategic expansion of Biodeal’s manufacturing platform into sterile injectables for global markets, adding established regulatory credentials, specialised capabilities and significant manufacturing capacity to its portfolio.
The facility is equipped for general injectables and Carbapenem manufacturing in vial formats, supported by German-made Groninger processing lines, with current annual capacity of around 135 million units. There is scope to expand to the facility‘s full capacity of 17 production lines and to add pre-filled syringe (PFS) and lyophilised formats. Biodeal is pursuing PIC/S and EU accreditation for the facility as part of its plans to expand into additional regulated markets.
Spread across a 14-acre campus, the Paonta Sahib facility comprises approximately 39,000 square metres of built-up manufacturing space and has the potential to add a further capacity of 30 million units through near-term expansion. Located approximately 50 kilometres from Biodeal’s existing Nalagarh facility, the acquisition also strengthens the company’s manufacturing footprint within Himachal Pradesh’s established pharmaceutical corridor.
“This acquisition is a deliberate step, not an opportunistic one. RMB Capitalworks backed our growth path with conviction, and Paonta Sahib gives us a regulated-market manufacturing base with credentials and capabilities that normally take years to build. It changes the category of company Biodeal competes in and puts us in a strong position to continue building a durable, high-value regulated-market business,” said Anurag Kumar, Chairman & Managing Director, Biodeal Pharmaceuticals.
The facility was acquired from Biological E Limited, a Hyderabad-headquartered vaccine and pharmaceutical manufacturer with nearly seven decades of operations, as part of Biological E’s ongoing investment in its new vaccine R&D and CDMO campus in Telangana. With this acquisition, Biodeal adds established manufacturing capacity and credentials to its platform, broadening the range of complex injectable manufacturing it can offer pharmaceutical customers globally – spanning Carbapenems for serious bacterial and drug-resistant infections, and in process of expanding into ready-to-use pre-filled syringe formats, and lyophilised products with extended stability and shelf life.
“As Biological E continues to focus our investment on our new vaccine R&D and CDMO campus in Telangana, divesting our Paonta Sahib facility to a capable, growth-oriented partner was a natural next step. We are confident Biodeal Pharmaceuticals is well positioned to build on the strong foundation established at this facility, and we wish them continued success as they take it forward,” said Mahima Datla, CEO & Managing Director, Biological E Limited.
7, Oct 2026
Puri Airport Clears Final Environmental Hurdle, Construction Set to Begin
Puri, Oct 8 (UDN): The ambitious Shree Jagannath International Airport project in Puri has cleared a major regulatory hurdle with the Union Ministry of Environment, Forest and Climate Change granting final environmental clearance for the proposed greenfield airport.
Representational Image
The clearance paves the way for the next phase of the project and is expected to accelerate preparations for construction at Sipasarubali, where the airport is planned over nearly 471 hectares.
Puri Collector Dibyajyoti Parida said the environmental clearance has been granted, while certain formalities, including the required no-objection certificate from the Ministry, remain to be completed before construction activities can formally proceed.
“The EC has been accorded for the Puri airport project. A no-objection certificate thereafter is required from MoEFCC to go ahead with the project. The Airports Authority of India (AAI) will also give a go-ahead to prepare the detailed project report (DPR) to take up construction work,” Parida said.
Major Step Forward for Puri Airport
The project had earlier received Stage-I environmental clearance from the ministry on April 4, following the forest ministry’s in-principle approval and recommendations of the Expert Appraisal Committee.
Officials said the conditions attached to the initial clearance have since been addressed, paving the way for the final environmental approval.
With the final clearance in place, the forest land required for the airport project can formally be brought into the project framework, removing one of the key obstacles to its implementation.
Airport to Handle 4.6 Million Passengers Annually
The proposed airport is estimated to cost around Rs 5,631 crore and is planned across approximately 471 hectares (1,164 acres).
Once operational, the airport is expected to have a passenger-handling capacity of around 4.6 million passengers per annum.
According to officials, the runway will require 114.961 hectares, including around 3.427 hectares of forest land. A further 0.037 hectare of forest land will be required for construction of the passenger terminal building.
A Boost to Puri’s Connectivity
The proposed international airport is being viewed as a major infrastructure project for Puri and Odisha, particularly given the city’s status as a major pilgrimage and tourism destination.
The final environmental clearance is expected to give fresh momentum to the project, with the authorities now moving towards the remaining procedural approvals, preparation of the detailed project report and subsequent construction activities.
The project is expected to significantly strengthen air connectivity to Puri and support the growth of tourism and related economic activities in the region once completed.
7, Oct 2026
CDK Global Names Sudhakar Ramakrishna President and CEO
Technology veteran succeeds Brian MacDonald, who retires after leading successful CDK transformation
India, Oct 07: CDK, the leading automotive retail software provider, named Sudhakar Ramakrishna president and CEO and member of the CDK board of directors, effective Oct. 5. He succeeds Brian MacDonald, who will retire and serve as a senior strategic advisor to Brookfield and CDK, providing continuity and perspective through the planned transition.
Ramakrishna is a seasoned enterprise technology leader with decades of experience building and scaling software businesses across cloud, mobility, networking, security and collaboration markets. He most recently served as president and CEO of SolarWinds, a leading provider of infrastructure management software, and previously led Pulse Secure, where he worked closely with customers and partners in complex, mission-critical environments. He also held senior leadership roles at Citrix, Polycom, Motorola, 3Com and U.S. Robotics.
“We are grateful to Brian for his leadership and the lasting impact he has had on CDK. He returned to the company at an important moment and led a multi-year transformation that strengthened CDK’s strategy, product roadmap and financial foundation,” said Doug Bayerd, managing partner in Brookfield’s Private Equity Group and director of CDK’s board of directors. “Sudhakar is the right leader to build on that foundation. His experience leading technology organizations, scaling innovation and commercializing customer-centric products makes him well suited to advance CDK’s momentum and help its customers succeed in a changing automotive landscape.”
CDK enters this transition positioned for its next phase of growth, supported by more than $500 million invested over several years to evolve its platform from an industry-leading system of record into a system of intelligence and engagement. As technology becomes more central to automotive retail, CDK’s unmatched automotive-specific data -including 257 million unique customer IDs reflecting most U.S. consumers and vehicles on its platform – creates a strong foundation for AI, analytics and customer insights. That advantage allows CDK to embed intelligence directly into the workflows customers already rely on without disruption.
“CDK has the people, scale, expertise and product depth to help customers get more from the solutions they rely on to operate their businesses,” said Ramakrishna. “Our opportunity is to deliver more customer value and success through innovation, disciplined execution and reliable delivery. I look forward to spending time with our customers, learning from our teams and partners, and carrying forward our commitment to earning the industry’s trust every day.”
7, Oct 2026
WHO Says Risk of Plague Spread Remains ‘Very Low’ Amid Russia Concerns
United Nations, Oct 8: The World Health Organization (WHO) has assessed the risk of the plague spreading beyond a suspected incident in Russia as “very low”, even as international concern grows over the death of a technician linked to a plague research facility in Siberia.
Representational Image
WHO spokesperson Christian Lindmeier said Tuesday that authorities had identified and were monitoring people who had been in contact with the deceased woman. So far, none of the contacts has developed symptoms associated with plague.
“According to the test results, no pathogens of dangerous infectious diseases were detected among any of the contacts,” Lindmeier told reporters in Geneva.
The WHO currently assesses the risk as moderate to low in Irkutsk, where the incident occurred, low for Russia as a whole, and very low for the WHO European Region, Lindmeier said.
The technician, who worked at a research institute studying dangerous pathogens, reportedly died last week after developing pneumonia. Russian authorities said her illness initially appeared to be a typical acute respiratory viral infection.
Media reports have suggested that she may have fallen ill after accidentally breaking a test tube at the facility last month. However, the circumstances surrounding her illness and death remain under investigation.
The research institute is located in Siberia, a region where plague occurs naturally among wild animals. The WHO said it contacted Russian authorities after reports of the death emerged and is continuing to monitor developments.
US Watching Situation Closely
The incident has also drawn attention in Washington. US Secretary of State Marco Rubio said the United States was monitoring the situation “very closely, hour by hour”.
Rubio said there could be nothing unusual about the incident but acknowledged that it remained unclear whether the situation was more serious than initially believed. He also called on Moscow to share further information with the international community.
The heightened concern comes against the backdrop of continuing debate over the origins of the COVID-19 pandemic and the possibility of laboratory-related incidents involving dangerous pathogens.
Russian authorities, meanwhile, have sought to reassure the public. Kremlin spokesman Dmitry Peskov said the country’s health watchdog, Rospotrebnadzor, was closely monitoring the situation and urged people not to rely on rumours or speculation.
What Is Plague?
Plague is an infectious disease caused by the bacterium Yersinia pestis, which is primarily found in small mammals and their fleas. Humans can become infected through flea bites or direct contact with infected tissues. Pneumonic plague can also spread through respiratory droplets from an infected person or animal.
The most common form, bubonic plague, causes painful swelling of the lymph nodes, known as buboes. More severe forms include septicaemic plague, which affects the bloodstream, and pneumonic plague, which affects the lungs.
Despite the concerns surrounding the Russian incident, the WHO’s current assessment indicates that the risk of wider international transmission remains very low.
7, Oct 2026
UAE-Founded AHOY Labs Outperforms OpenAI, Amazon,Microsoft, Google and NVIDIA on EnterpriseRAG-Bench
Regional deep-tech company delivers greater enterprise AI accuracy than OpenAI, with a fifteenth of the noise
Dubai, UAE,7 October 2026–UAE-founded AHOY Labs (aka Trouvé), part of the AHOY technology group, today announced that its sovereign-by-design AI system has outperformed the enterprise AI search products of OpenAI, Amazon, Microsoft, Google and NVIDIA on EnterpriseRAG-Bench, a public, open-source benchmark for enterprise AI.
The regional deep-tech company surpassed all five across every measure reported by the benchmark and ranked eighth worldwide among 26 systems.
The benchmark gives each AI system the full archive of a simulated company including 500,000 emails, chat threads, files,tickets, sales recordsand meeting transcripts. It then asks 500 questions.Some answers are spread across several documents. Some documents contradict each other. Some questions have no answer at all. Systems are scored on whether their answers are correct and completeand on whether they bring back only the documents that matter.
“We built AHOY to prove that sovereignty and world-class performance are not a trade-off. Outperforming the biggest names in technology, on both accuracy and precision, shows that regionalorganisations can keep full control of their data without settling for second-best AI. This is a milestone, not a finish line. Our goal is the top spot,” said Jamil Shinawi, Founder and Group CEO of AHOY.
A fifteenth of the noise
The biggest gap is in precision. For each answer, OpenAI File Search returned an average of 15.7 irrelevant documents. AHOY Labs returned 1.03, about a fifteenth as many and the fewest of all six systems. Irrelevant documents are noise: they bury the real evidence, add cost and slow people down. They also make it harder to check where an answer came from. With AHOY, the evidence behind an answer is the evidence that matters. For governments, regulators and organisations that must defend every decision they make with AI, that difference is decisive.
Built for sovereignty
AHOY’s platform is designed to run inside the customer’s own premises, on the customer’s own hardware. It can operate fully offline, so sensitive data never leaves the organisation, and AHOY’s internal testing shows it delivers the same benchmark result when running fully offline. Sovereignty is built into the system itself, not added as a hosting option, so every AHOY deployment is sovereign. This makes AHOY Labs the highest-ranked sovereign system on the leaderboard and suited to sectors where data cannot go to a public cloud, such as government, defence, healthcare and energy.
EnterpriseRAG-Bench was created by Onyx and published with an accompanying research paper. It is open source under the MIT licence. Onyx reviews results before posting them to the public leaderboard and does not rank its own product.
Overall Score of Systems:
|
System |
Overall score |
Questions answered correctly |
Irrelevant documents per answer (lower is better) |
|
AHOY Labs (aka Trouvé) |
74.95 |
79.6% |
1.03 |
|
OpenAI File Search |
61.03 |
69.8% |
15.7 |
|
Amazon Q (Kendra) |
48.96 |
55.4% |
1.49 |
|
Microsoft Azure AI Search |
48.42 |
56.4% |
3.25 |
|
Google Vertex AI Search |
41.87 |
49.2% |
4.05 |
|
NVIDIA AI Blueprints |
37.73 |
59.6% |
7.72 |
7, Oct 2026
Zapata Quantum Joins IBM Quantum Network to Accelerate Mission-Driven Quantum Application Development
Effort builds on prior collaboration to translate high-value use cases into practical applications running on IBM quantum computers
BOSTON, Massachusetts – October 7, 2026 – Zapata Quantum (OTCQB: ZPTA) (“Zapata” or the “Company”) today announced it has joined the IBM Quantum Network with plans to use IBM’s world-class quantum computers with Zapata’s deep expertise in use-case discovery and application development. The Company’s effort aims to help close the quantum application gap by translating advances in quantum computing into mission-critical applications and real-world impact.
“The rapid progress IBM is making on the path to fault-tolerant quantum computing brings the quantum application gap into sharper focus,” said Sumit Kapur, CEO of Zapata Quantum. “These advances must be matched by progress in identifying, evaluating and developing the applications that will deliver real-world value. We are excited for Zapata’s Quantum Application Intelligence™ to translate organizations’ highest-mission priorities into practical quantum applications.”
“IBM’s roadmap to fault-tolerant quantum computing is one of the most credible in the industry, and superconducting qubits remain one of the most capable paths to advantage because their hardware is fast,” said Jonny Olson, VP Strategy and Co-Founder of Zapata Quantum. “Joining the IBM Quantum Network lets us better identify valuable opportunities for organizations that need the fastest systems, and then prepare those organizations for the precise moment that quantum gives them real ROI.”
Joining the IBM Quantum Network builds on a history of joint IBM and Zapata research done on early quantum devices. Zapata used IBM quantum computers in a landmark study published in Nature Biotechnology that produced experimentally validated candidates targeting KRAS and was selected as one of the journal’s Top 10 Articles of 2025.¹ Scientists from the two companies also co-authored research published in npj Quantum Information, which advanced the understanding of variational quantum factoring on a superconducting processor.2
Being part of the IBM Quantum Network also reflects Zapata’s broader strategy of working with technology leaders across the quantum and AI ecosystems. Insights from being part of the IBM Quantum Network will inform Quantum Pilot™, Zapata’s hardware-agnostic platform that helps enterprises identify, prioritize, and develop quantum applications as hardware matures.
7, Oct 2026
Riverain Technologies Expands Access to ClearRead™ Advanced Chest Imaging AI Through RapidAI’s Enterprise Platform
ClearRead Chest integration extends Riverain’s clinically proven cardiothoracic AI suite of solutions through a unified enterprise workflow designed to reduce fragmentation and accelerate action
MIAMISBURG, Ohio, October 7, 2026 — Riverain Technologies, a leader in cardiothoracic imaging AI, today announced that its FDA-cleared ClearRead™ Chest suite will be available through RapidAI, a global leader in enterprise clinical AI, via its Rapid Enterprise™ Platform. The integration expands access to Riverain’s advanced lung and cardiac imaging intelligence within RapidAI’s connected enterprise platform, helping radiologists identify subtle findings, reduce cognitive burden, and move from imaging insight to clinical action with less workflow friction.
Designed for chest CTs and X-rays, ClearRead Chest is a cardiothoracic AI suite that helps radiologists detect, characterize and visualize pulmonary nodules, pneumothoraces, and coronary artery calcification (CAC). Riverain’s patented vessel and bone suppression technology provides an unobstructed view of the lungs to improve visualization of nodules and other pathology. The ClearRead Chest suite delivers clinically proven accuracy and time-saving insights within radiologists’ existing workflows, helping ease cognitive burden and support more confident decisions.
Riverain develops clinically validated cardiothoracic imaging technology designed to help radiologists see, detect, characterize, and report subtle findings more clearly. Integrating ClearRead Chest into RapidAI’s connected platform extends the technology into an enterprise environment that unifies imaging intelligence, clinical workflows, and patient management, helping health systems scale AI without adding separate systems or operational complexity.
ClearRead Chest integrates into the Rapid Enterprise Platform, including its Rapid Edge Cloud™ infrastructure, the Rapid Navigator Pro™ radiology workflow solution, RapidAI’s mobile and web applications, and its AI governance capabilities. The integration will create a secure, interoperable experience across PACS, EHR, and reporting systems, allowing health systems to deploy Riverain’s cardiothoracic imaging intelligence while maintaining workflow consistency and enterprise-grade infrastructure.
“ClearRead was developed to help radiologists see subtle chest findings more clearly and confidently within the workflows they already rely on every day,” said Steve Worrell, CEO of Riverain Technologies. “By integrating ClearRead Chest into the Rapid Enterprise Platform, we’re expanding access to our advanced chest imaging technology to support earlier detection of leading global killers like lung cancer, and cardiovascular disease and reduce the burden on radiologists facing increasingly complex imaging workloads.”
Through the integration, Riverain’s ClearRead Chest suite will be available to RapidAI’s install base of more than 2,500 hospitals. The collaboration gives Riverain a broader path to scale advanced cardiothoracic imaging intelligence across health systems while allowing customers to access Riverain and RapidAI solutions through one connected workflow.
For Riverain, the collaboration advances its mission to reduce delayed cardiothoracic diagnoses by bringing ClearRead Chest to more radiologists within the systems they use every day. For RapidAI, the integration expands its enterprise imaging ecosystem with clinically validated third-party AI for lung and cardiovascular disease, building on its full-body portfolio.
7, Oct 2026
MedScout Launches Scout AI and the MedScout MCP to Advance Commercial Intelligence for MedTech Teams
Scout AI builds target lists, briefs, outreach and routes inside MedScout, while the MedScout MCP brings that intelligence into Claude, Copilot, Gemini and ChatGPT.
AUSTIN, Texas (October 7, 2026) – MedScout, the commercial engine for MedTech, today announced the launch of Scout AI, which turns data and insights into complex analyses, target lists, meeting briefs, physician outreach and daily routes reps can work the same day. Scout AI puts that intelligence to work inside MedScout, and the MedScout MCP brings it into Claude, Copilot, Gemini and ChatGPT.
Scout AI takes manual, time-consuming tasks, like building target lists and prepping for meetings, and does the work in seconds. A rep can ask for the top providers in a given city on a given day, and Scout AI identifies the providers, determines where each is likely to be, and builds and optimizes a route in one step. Scout AI draws on MedScout’s data covering procedure volume, referral patterns, payer mix, reimbursement, sites of care and industry payments to build the workflow.
Teams can use Scout AI to:
-
Size a market before making a move, from deciding where the next rep should go to backfilling a role, with volume trends, payer mix, site of care, and reimbursement for one territory or two side by side.
-
Find best-fit providers that meet every targeting criterion at once, such as surgeons performing robotic procedures at hospitals but not at the system-affiliated ASCs, with no payments from a named competitor
-
Map referral networks and patient journeys to see who sends a provider their patients and where those patients go next
-
Build routes ordered around drive time and the days providers are actually on site.
-
Draft personalized outreach that providers are more likely to respond to, citing trends in their market, where referrals are going, and more.
-
Get pre-meeting briefs on a provider’s procedures, patient population, affiliations and payer mix, framed around how to approach them.
“For the past five years, we’ve worked hard to deeply understand our customers: their products, their teams, their strategies, and the impact they have on people’s lives,” said Skylar Talley, co-founder and CEO of MedScout. “MedScout.AI builds everything we’ve learned into software that actually does the work for commercial teams and delivers insights wherever they need them. I’m grateful to the more than 20 design partners who helped us build it. By this time next year, I believe our customers will think of Scout as a teammate, not a tool.”
The MedScout MCP connects MedScout to the AI platforms commercial teams already work in, including Claude, Copilot, Gemini, and ChatGPT. It is built for teams that want to combine MedScout’s market data with their own CRM, ERP, billing or pricing data, such as finding high-volume providers who aren’t in the CRM yet, or target accounts that haven’t had a billing event. MedScout Strategies, code sets, territories and permissions carry through the connection, so teams get the same governed answers in either place.
“With the MedScout MCP, our team pulls market insights right into Claude, where they accelerate quality outputs,” said Matt Wallace, Vice President of Sales at Magnus Medical. “In the past month alone, we’ve cut hospital executive briefs from days to minutes, and we keep finding new use cases for MSA targeting and bespoke market analysis.”
Scout AI and the MedScout MCP run on the same claims-based intelligence, covering more than 330 million patient lives, more than 3.7 million healthcare providers and more than 700,000 sites of care. Scout AI is available today to MedScout customers in the MedScout web and mobile apps, with no setup required, and the MedScout MCP is available to all MedScout customers, with a two-week trial open to industry professionals. Both are part of a broader rebuild of the MedScout product suite around AI, with more to be announced later this year. To learn more or see Scout AI in action, visit medscout.io.
